Unknown PHASE2 INTERVENTIONAL 1-arm NCT01774058

The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation (ILOFLOW)

The Intraoperative Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation in Diabetics and Non-diabetics: Implication for Outcome-prediction and Perioperative Therapy

Sponsor: Prim PD Dr Afshin Assadian

Conditions Arteriosclerosis Diabetes Neuropathy Peripheral Arterial Occlusive Disease

Interventions Ilomedin

Updated 7 times since 2017 Last updated: Oct 16, 2018 Started: Oct 31, 2012 Primary completion: Jun 30, 2019 Completion: Jun 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01774058, this PHASE2 trial focuses on Arteriosclerosis and Diabetes and remains ongoing. Sponsored by Prim PD Dr Afshin Assadian, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Nov 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Nov 2018 — Nov 2020 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Prim PD Dr Afshin Assadian
Wilhelminenspital Vienna

Data source: Wilhelminenspital Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria